MERIDIAN BIOSCIENCE REPORTS SECOND BEST QUARTER IN COMPANY HISTORY
CINCINNATI, Feb. 4, 2022 /PRNewswire/ — Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the first quarter ended December 31, 2021. First Quarter Fiscal 2022 Highlights (Comparison to First Quarter Fiscal 2021): Consolidated net revenues of $88.3 million, second best in company history with both segments ahead of expectations Life Science segment delivered net revenues of $55.1 million Diagnostics […]